Literature DB >> 20048433

[Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers].

Einosuke Mizuta1, Toshihiro Hamada, Osamu Igawa, Chiaki Shigemasa, Ichiro Hisatome.   

Abstract

In hypertensive subjects, their serum uric acid levels tend to be higher because of decreasing urinary secretion or overproduction of uric acid. Among calcium channel blockers (CCBs) , long acting nifedipine and cilnidipine reveal serum uric acid lowering action. They decrease the production of uric acid precursor in skeletal muscles under anaerobic condition induced by hypertension or insulin resistance. Hyperuricemia is considered to be a risk factor of not only gout but also renal and cardiovascular diseases, thus, it is important to use CCBs without adverse effect on uric acid metabolisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048433     DOI: CliCa10014550

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  2 in total

1.  Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.

Authors:  Alberto F Rubio-Guerra; Ana K Garro-Almendaro; Cesar I Elizalde-Barrera; Juan A Suarez-Cuenca; Montserrat B Duran-Salgado
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-12-08

2.  Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study.

Authors:  Hiroko Abe; Tomoya Mita; Risako Yamamoto; Koji Komiya; Minako Kawaguchi; Yuko Sakurai; Tomoaki Shimizu; Chie Ohmura; Fuki Ikeda; Ryuzo Kawamori; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2012-10-22       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.